In the last few years, survival of patients infected with human immuno
deficiency virus (HIV) has been improved because of a decreased incide
nce of some opportunistic complications attributable to prophylactic t
reatments and antiretroviral drugs. The impact of these agents should
also be reflected in the quality of life (QoL) of patients. We have re
viewed this topic with an emphasis on different types of measurements
such as Q-TWIST, MOS and the Spitzer score which seem to be most appro
priate for this patient population. We do not think that a special typ
e of assessment should be designed for HIV-infected persons. It would
be less time-consuming to improve already existing validated scores fo
cusing on HIV infection. QoL in intravenous drug users with HIV should
be evaluated more often.